The management of bladder cancer, initially exclusively surgical, was recently improved by the development of chemotherapy.
Chemotherapy can thus be proposed as bladder instillations in order to prevent recurrences of non-muscle-invasive cancer (NMIC), and systemically in case of muscle-invasive cancer (MIC). Chemotherapy can then be administered prior to surgery (neoadjuvant), as a complement to surgery (adjuvant), as an alternative to surgery as part of a multimodality treatment, and alone in palliative intent in case of metastatic cancer. Renal function and general health status of the patient help the decision-making and the choice of the chemotherapy regimen, which should be validated during a multidisciplinary meeting and presented to the patient during a dedicated medical and paramedical appointment.
Prog Urol. 2015 Jul 21. pii: S1166-7087(15)00219-5. doi: 10.1016/j.purol.2015.06.011. [Epub ahead of print]
[Article in French]
Fiard G1, Pavillet J2.
1 Service d'urologie et de la transplantation rénale, CHU de Grenoble, CS10217, 38043 Grenoble cedex 09, France; Laboratoire TIMC-IMAG, CNRS, université Grenoble Alpes, 38000 Grenoble, France.
2 Service d'oncologie médicale, CHU de Grenoble, CS10217, 38043 Grenoble cedex 09, France.